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Background: It is unknown whether food allergy (FA) in an unselected population is comparable to those from an
outpatient clinic population.
Objective: To discover if FA in a random sample from the Dutch community is comparable to that of outpatients.
Methods: This study was part of the Europrevall-project. A random sample of 6600 adults received a questionnaire.
Those with symptoms to one of 24 defined priority foods were tested for sIgE. Participants with a positive case
history and elevated sIgE were evaluated by double-blind placebo-controlled food challenge (DBPCFC). Outpatients
with a suspicion of FA were evaluated by questionnaire, sIgE and DBPCFC.
Results: In the community, severe symptoms were reported less often than in outpatients (39.3% vs. 54.3%).
Participants in the community were less commonly sensitized to any of the foods. When selecting only those with
a probable FA (i.e. symptoms of priority food and elevation of sIgE to the respective food), no major differences
were observed with respect to severity, causative foods, sensitization and DBPCFC between the groups.
Conclusion: In the Netherlands, there are large differences in self-reported FA between community and outpatients.
However, Dutch community and outpatients with a probable FA do not differ with respect to severity, causative foods,
sensitization and DBPCFC-outcome.
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A recent meta-analysis showed that self-reported preva-
lence of food allergy (FA) ranged from 3% to 35% in
adults [1]. However, the prevalence of FA as diagnosed by
double-blind placebo-controlled food challenge (DBPCFC)
is estimated to be around 2% to 4% for adults [2-7].
A study from a regional allergy center in the UK,
serving a population of 1.6 million, reported a population
prevalence of 0.03%, being a factor of 100 less than in
population-based studies. This suggests that a minority
of FA patients present to their GP and are subsequently
referred [8].* Correspondence: t.t.m.le-2@umcutrecht.nl
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unless otherwise stated.Most studies investigating the clinical aspects of FA
involve patients from a (tertiary) allergy clinic. Since
only a fraction of food allergic individuals from the gen-
eral population visit a doctor, [8] it is not clear how rep-
resentative results from such studies are for the general
population. However, studies comparing FA between the
community and outpatients are lacking.
The aim of this study was to investigate to what extent
FA in a random sample of the Dutch community is com-
parable to FA in outpatients.
Methods
This study was part of the EuroPrevall-project, a multi-
disciplinary European project investigating several as-
pects of FA [9]. It consisted, among many different, of
an epidemiological element investigating the prevalenceis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ent. This study was approved by the local medical ethical
committee (METC) of the University Medical Center
Utrecht.
Community
The epidemiological study consisted of three stages and
is described in detail elsewhere [10]. In short, the study
took place from October 2006 until March 2009. The
1st stage was a population-based study in which a short
questionnaire to screen for FA was sent out to a random
sample of 6600 adults aged 20–54 years living in the city
of Utrecht, The Netherlands.
In the 2nd stage, all those who in the screening ques-
tionnaire reported to have experienced adverse reactions
to one of the 24 preselected priority foods (hen’s egg,
cow’s milk, peanut, soy, hazelnut, walnut, celery, kiwi,
apple, peach, sesame, mustard, wheat, fish and shrimp,
buckwheat, corn, carrot, tomato, melon, banana, lentils,
sunflower, poppy seeds) were invited to come to the hos-
pital for a detailed questionnaire and serum IgE testing .
In the 3rd stage, participants with self-reported symp-
toms and sIgE to at least one of the priority foods were
called in for DBPCFC and a full clinical evaluation, iden-
tical to that of the outpatients (see below).
Outpatients
The outpatient study took place from January 2006 until
June 2009. All adult patients (age 18 years and older)
who were referred to our tertiary allergy centre with a
suspected FA, were asked to participate in the EuroPrevall
outpatient clinic study. Inclusion criteria were symptoms
developing within 2 hours after ingestion of a food.
Participating outpatients underwent a clinical evaluation
comprising a thorough medical history using a standard-
ized questionnaire, sIgE testing and DBPCFC.
Clinical evaluation
All clinical information was collected following a stan-
dardized questionnaire which was specifically developed
for the Europrevall-study. Symptoms were classified into
mild (symptoms of the oral cavity), moderate (gastro-in-
testinal symptoms and symptoms of the skin and
mucous membranes) and severe (respiratory or cardio-
vascular symptoms).
A probable FA was defined as symptoms within
2 hours and sIgE ≥0.35 kUA/L to a priority food. Al-
though DBPCFC is the gold standard for diagnosis of
FA, diagnosis of FA in majority of patients in clinical
practice is based on medical history and sIgE. Therefore,
in this study we chose a pragmatical approach using a
suggestive history (i.e. symptoms <2 hours of ingestion)
together with IgE sensitization to define a probable FA.In vitro diagnosis
sIgE testing for all priority foods were performed in a
single laboratory using the ImmunoCAP system and re-
agents from Phadia (Thermo Fisher Scientific, Uppsala,
Sweden). sIgE values of ≥0.35 kUA/L were regarded as
positive.
DBPCFC
All participants with symptoms to hen’s egg, cow’s milk,
peanut, hazelnut, celery, apple, peach, fish or shrimp
were asked to participate in DBPCFC. A detailed proto-
col of the EuroPrevall DBFCFC is described elsewhere
[11]. Briefly, active and placebo provocations were ran-
domly performed on two different days with eight in-
creasing doses. The single doses were administered at an
interval of at least 20 minutes up to the top dose. The
interval could be extended at the request of the patient,
according to the case history of the patient, or in case of
severe persisting subjective symptoms. Challenges were
discontinued after the dose leading to the first objective
allergic symptoms or ingestion of the whole meal. Ob-
jective symptoms considered for discontinuation of the
provocation were blisters of the oral mucosa, skin symp-
toms such as flush, urticaria, angioedema, rhinitis, con-
junctivitis, drop of blood pressure of at least 20 mmHg,
drop of FEV1 > 12% or PEF ≥ 20%, laryngeal oedema,
diarrhoea, emesis or in case of severe persistent subject-
ive symptoms lasting for more than 45 minutes such as
severe itching of palms, soles, head or severe gastric/ab-
dominal pain. If all DBPCFC doses were negative, pa-
tients underwent an open food challenge. Patients that
had a reaction of any type and any duration on the ac-
tive day and no reaction on the placebo were classified
as reactors, patients that did not react on the active nor
the placebo day were tolerant and patients that reacted
on the placebo day were placebo responders.
Statistics
Chi-square tests and, where appropriate, Fisher’s exact
tests were used to test the differences in several clinical
characteristics (i.e. gender, severity of symptoms, causa-
tive foods, atopic diseases, sensitization and DBPCFC
outcome) between the community and outpatients. Dif-
ferences in age and the number of causative foods
between the two groups were calculated using Student’s
T-test and, where appropriate, Mann–Whitney U test.
Statistical analysis was performed using SPSS version 20
(SPSS Inc., Chicago, Illinois, USA) for Windows.
Results
Study population
Of the screening questionnaires that were sent out to a
random sample of 6600 adults, 3864 responded, of
whom 967 (25.0%) reported adverse food reactions to
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(Figure 1). 154 of these 416 (37.0%) were willing to come
to our clinic for the second stage consisting of a detailed
questionnaire and sIgE testing. In 37.7% (58/154) sIgE
was positive for the respective food. Of these 58 cases,
46 entered the 3rd stage for a full clinical evaluation.
In the outpatient clinical part of the study, all outpa-
tients that met the inclusion criteria agreed to partici-
pate in the study. In total, 133 outpatients that were
referred to our allergy center were included during the
study period. Symptoms to at least one priority food
were reported by 127 outpatients, in 102 of which sIgE
to the same food(s) was detected.
Reported adverse food reactions to any food in the
community
Adverse reactions to any food were reported by 25.0%
of the responders in the community. Cow’s milk (10.7%),
nuts (9.5%), apple (9.4%) and fish (6.3%) were the most
commonly reported causative foods. Mild symptoms
(consisting of only oral allergy symptoms) were reported
by 10.1%, moderate symptoms by 58.4% and severe
symptoms by 21.4% of participants. In the group with
moderate symptoms, gastro-intestinal symptoms dominated
(60.2%).
Of the 967 participants reporting adverse reactions
to any food, 416 reported symptoms to priority food
and 551 reported symptoms to other foods. These two
groups were compared and showed that the group with
symptoms to priority food significantly more often re-
ported oral allergy symptoms (51.5% vs. 24%), difficulty1st stage:                       6
Screening questionnaire 
                     
967/3864 
     416/3864 
2nd stage:             1
Case-control study     
     58 positive histo
                     
3rd stage:                           46
DBPCFC:       
      18
Figure 1 Flow-diagram of the epidemiological part of the study in thwith swallowing (15.9% vs. 6.3%) and breathlessness
(11.3% vs. 6.8%). In the group with symptoms other than
priority food gastro-intestinal symptoms dominated and
was significantly higher than in the priority food group
(47.7% vs. 38.6%). Furthermore, the group without symptoms
of priority food significantly more often reported that
the symptoms to the culprit food took place once only
(26.8%).
Reported adverse reactions to priority foods in
community and outpatients
Of the participants reporting adverse reactions to any
food (n = 967), 43.0% reported symptoms to at least one
of the priority foods. Walnut, apple, cow’s milk, hazelnut
and kiwi were the most commonly reported priority
foods in the community (Table 1, 2nd stage). The fre-
quency of severe symptoms rose from 21.4% in the 1st
stage to 39.3% in the 2nd stage in participants from the
community. Remarkably, only a small percentage of par-
ticipants from the community who reported symptoms
to priority foods also had a positive sIgE for the respect-
ive food (Figure 2).
When comparing the community to outpatients, using
reported symptoms to priority food as selection in both
groups, it appeared that severe symptoms were signifi-
cantly more common in outpatients (54.3% vs. 39.3%,
p = 0.008). The frequency in which the different priority
foods were reported, differed significantly for some
foods: in the community the frequency of allergy to
cow’s milk, fish and shrimp was significantly higher,
whereas outpatients reported symptoms to peanut,600 questionnaires sent out 
        3864 responded 
reported symptoms to any food (25%) 
reported symptoms to priority food  
        (10.8%)
54/416 willing to participate        
ry and positive serum IgE for priority food 
              (38%) 
/58 detailed questionnaire 
    
 participated in DBPCFC (39%) 
e community.
Table 1 Patient characteristics of the three different stages
1st stage (possible FA
to any food)||
2nd stage (possible FA to priority
food)‡
3rd stage: (probable FA to priority
food)§
Community
(n = 967) %
Community
(n = 154) %
Outpatients
(n = 127) %
p-value Community
(n = 46) %
Outpatients
(n = 102) %
p-value
Male gender 32.0 31.2 35.4 0.52 30.4 38.2 0.36
Age (mean ± SD) 34.7 (±9.3) 34.1 (±9.2) 32.2 (±12.3) 0.16 35.3 30.4 0.01*
Number of foods causing
symptoms (median (range))
4 (1-17) 5 (1-18) 0.40 6 (1-14) 6 (1-18) 0.96
Symptom¦:
-mild 10.1 14.0 26.0 0.01* 26.1 21.0 0.50
-moderate 58.4 46.7 19.7 <0.001* 28.3 19.0 0.21
-severe 21.4 39.3 54.3 0.008* 45.7 60.0 0.11
Atopy:
-pollen allergy 70.8 94.5 <0.001* 97.8 94.1 0.44
-dermatitis 36.4 33.3 0.61 25.6 37.8 0.18
Symptoms of plant food
-Hazelnut 2.4 31.2 32.3 0.84 71.7 37.3 <0.001*
-Peanut 2.7 16.2 32.3 0.002* 18.6 34.3 0.04*
-Walnut 2.5 36.4 36.2 0.98 52.2 41.2 0.21
-Apple 9.4 33.1 53.5 0.001* 82.6 57.8 0.003*
-Peach 1.0 18.8 29.1 0.04* 50.0 34.3 0.07
-Kiwi 4.8 29.2 43.3 0.01* 34.8 40.2 0.53
-Melon 1.2 14.9 15.0 1.00 21.7 16.7 0.46
-Banana 1.4 11.0 17.3 0.17 17.4 18.6 0.86
-Tomato 2.8 13.0 17.3 0.31 13.0 18.6 0.40
-Carrot 1.8 8.4 11.8 0.42 19.6 14.7 0.46
Symptoms of animal food
-Cow’s milk 10.7 31.8 8.7 <0.001* 4.3 6.9 0.72
-Hen’s egg 2.4 7.8 8.7 0.79 2.2 8.8 0.17
-Fish 6.3 18.2 5.5 0.001* 6.5 5.9 1.00
-Shrimp 3.7 20.8 10.2 0.02* 8.7 10.8 0.78
FA = food allergy.
¦mild = oral allergy symptoms, moderate = gastro-intestinal symptoms or symptoms of the skin and mucous membranes, severe = respiratory or cardiovascular symptoms.
||reported adverse food reaction to any food.
‡positive history for priority food.
§positive history and serum IgE for priority food.
*p-value < 0.05.
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(Table 1, 2nd stage). Outpatients had significantly more
clinically relevant sIgE sensitisation compared to the com-
munity for all foods, except for hazelnut and apple, where
no difference was seen between both groups (Figure 2).
In summary, causative foods, severity and relevant
food sensitization differed between the community and
outpatients when only selecting on self-reported symp-
toms to priority foods.
Probable FA in community and outpatients
Of the participants from the community that reported
symptoms to a priority food, 58/154 (37.7%) also had apositive sIgE for that food. These participants were
considered to have a probable FA. When comparing the
community participants and outpatients, using symp-
toms and sIgE to priority food as selection in both
groups (i.e. probable FA), the differences in causative
foods as seen in the 2nd stage disappeared largely. Only
hazelnut and apple were significantly more frequently
reported as a causative food in the community, whereas
peanut was more commonly reported in outpatients
(Table 1). In contrast to the 2nd stage, no differences
were seen in the severity of symptoms between the com-
munity and outpatients (Table 1). Whereas in the 2nd
stage major differences were observed between the two
sIgE in 3rd stage
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Figure 2 Percentage of positive sIgE in the community and outpatients with symptoms to the food in the 2nd stage (reported
symptoms) and 3rd stage (reported symptoms and positive sIgE for at least 1 food) of the study. The number (n = ..) between brackets
indicates the total number of the community and outpatients that reported symptoms to that respective priority food. *p-value <0.05.
Le et al. Clinical and Translational Allergy  (2015) 5:8 Page 5 of 8groups in sensitization to most priority foods, these dif-
ferences disappeared largely when selecting on FA
(Figure 2). Table 2 shows the clinical characteristics in
more detail for the main foods. The majority with a
probable food allergy were birch pollen sensitized, had
symptoms within a few minutes after ingestion of the
culprit food and oral allergy symptoms was the most
common symptom. A probable cow’s milk en hen’s egg
allergy was rare in our adult population. In those with a
cow’s milk and hen’s egg allergy anaphylaxis was rela-
tively frequent (25%).
In total 18 participants from the community and 30
outpatients underwent DBPCFC. There were no signifi-
cant differences in the severity of symptoms for the indi-
vidual foods between those who agreed to participate in
DBPCFC and those who declined (p > 0.05, data not
shown). The percentage of positive DPBCFC did not dif-
fer between community and outpatients (77.8% vs.
63.3%, p = 0.47). Of the patients with a positive
DBPCFC, 35.7% of the community and 31.6% of outpa-
tients (p = 0.80) had objective signs. In both groups, the
percentage of placebo reactors was high: 16.7% in the
community and 20% in the outpatients. All placebo reac-
tors reported subjective symptoms and not objective
signs on placebo day. The outcome of the challenges per
food are shown in Table 3.
In conclusion, when focusing on a probable FA, no
difference could be demonstrated between the commu-
nity participants and the outpatients with regard to se-
verity, causative foods, relevant food sensitization and
DBPCFC-outcome.Discussion
Since most studies investigating FA use outpatients as a
study population, the question arises whether such studyresults are applicable to food allergic persons in the
community.
To our knowledge this is the first study to compare
FA in the community and outpatients. In this study we
found that, when focusing on self-reported symptoms to
priority foods, there are large differences in causative
foods, severity and relevant food sensitization between
community and outpatients. However, when selecting
those with a probable FA, as defined by reported symp-
toms to priority food together with a positive sIgE to the
respective food, it became evident that the differences in
the community and outpatients disappeared. This indi-
cates that patients with a probable FA seen in a tertiary
outpatient allergy center are not different from those
with a probable FA in the community.
Previous population based studies showed that the
prevalence of self-reported FA to any food varied from
3% to as high as 35%, whereas the prevalence of true FA
is estimated to be 2-4% [1-7,12-14]. In our study we
confirmed for the Dutch population the discrepancy be-
tween the prevalence of self-reported adverse food reac-
tions (10.8%), a FA as defined by a suggestive history
and supported by sIgE (4.1%) and a FA confirmed by
DBPCFC (3.2%).
Since non-response bias could play a role in the com-
munity survey, we performed a non-response analysis.
The response rate in the 1st stage of the community sur-
vey was 61%. We calculated the cumulative prevalence
of adverse food reaction at the time of response to ex-
trapolate the prevalence to non-responders [15]. This
showed that the cumulative prevalence of adverse food
reaction stabilized after a response rate of 40%, indicat-
ing that non-response bias does not play a major role in
the 1st stage of the study. For the 2nd stage, we com-
pared age, gender, doctor-diagnosed FA and the symp-
toms between responders and non-responders. Only the
Table 2 Clinical characteristerics per food in patients with a probable food allergy (i.e. symptoms and specific IgE)
Community Outpatients
Symptoms Time interval sIgE
food
Birch
IgE*
Symptoms Time interval sIgE
food
Birch
IgE*
N OAS (%) skin
(%)
GI
(%)
Resp
(%)
Cardio
(%)
Anaph
(%)
<5
min
5-
30
min
30-
120
min
>
2
hrs
Median
(Range)
(%) N OAS
(%)
skin
(%)
GI
(%)
Resp
(%)
Cardio
(%)
Anaph
(%)
<5
min
5-
30
min
30-
120
min
>
2
hrs
Median
(range)
(%)
Hazelnut 33 90.9 27.3 6.1 42.4 0 0 84.8 9.4 6.3 0 12.5
(0.47-
74.99)
72.7 36 97.2 27.8 27.8 47.2 2.8 5.6 86.1 13.9 0 0 23.37
(0.65-
196.54)
97.2
Peanut 3 66.7 33.3 33.3 33.3 0 0 50 50 0 0 2.63
(0.60-
5.58)
100 27 88.9 59.3 29.6 48.1 0 0 77.8 22.2 0 0 2.21
(0.35-
321.78)
85.2
Walnut 2 100 50 50 50 0 0 100 0 0 0 1.04
(0.51-
1.58)
100 15 93.3 60 20 26.7 6.7 6.7 93.3 0 6.7 0 5.53
(0.36-
27.56)
93.3
Apple 33 97 24.2 21.2 24.2 0 0 75.8 21.2 3 0 1.49
(0.37-
21.18)
69.7 51 100 28 16 30 0 0 77.6 22.4 0 0 2.03
(0.42-
31.19)
100
Peach 22 95.5 31.8 13.6 27.3 0 0 77.3 18.2 4.5 0 2.00
(0.53-
12.91)
72.7 36 97.1 31.4 17.1 37.1 0 0 77.1 22.9 0 0 3.79
(0.59-
44.56)
100
Kiwi 6 100 33.3 16.7 16.7 0 0 100 0 0 0 1.07
(0.40-
11.21)
83.3 26 96.2 19.2 19.2 26.9 0 0 80 20 0 0 1.67
(0.35-
152.57)
88.5
Cow’s milk 0 - - - - - - - - - - - - 4 50 50 50 25 25 25 50 25 0 0 10.05
(0.43-
34.12)
50
Hen’s egg 0 - - - - - - - - - - - - 4 75 50 50 25 0 25 25 50 25 0 1.68
(0.40-
3.04)
75
OAS = oral allergy symptoms, GI = gastro-intestinal, Resp = respiratory, cardio = cardiovascular, anaph = anaphylaxis.
*Birch sIgE = sIgE birch ≥0.35.
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Table 3 Double-blind placebo-controlled food challenge (DBPCFC) in community and outpatients
Community Outpatients
N Positive
DBPCFC
(%)
Negative
DBPCFC
(%)
Placebo
reactor
(%)
Objective
signs* (%)
Subjective
symptoms*
(%)
N Positive
DBPCFC
(%)
Negative
DBPCFC
(%)
Placebo
reactor
(%)
Objective
signs* (%)
Subjective
symptoms*
(%)
Hazelnut 9 77.8 11.1 11.1 42.9 100 10 60 20 20 50 100
Peanut 1 100 0 0 0 100 9 66.7 22.2 11.1 50 100
Apple 5 60 0 40 33.3 66.7 8 50 12.5 37.5 0 100
Peach 2 100 0 0 0 100 1 100 0 0 0 100
Celery 1 100 0 0 100 100 0 - - - - -
Cow’s
milk
0 - - - - - 1 100 0 0 0 100
Hen’s
egg
0 - - - - - 1 100 0 0 0 100
* This is calculated as a percentage from those with a positive DBPCFC.
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in the responders (61% vs 49%, p = 0.02), which could in-
dicate that responders from the 2nd stage of the study
were more likely to have a probable food allergy com-
pared to non-responders. This would mean that the dif-
ferences found between community and outpatients in
the 2nd stage would even be larger. For the 3rd stage,
no differences were seen between responders and non-
responders with regard to age, sex and symptoms (data
not shown).
Although the response rate was low, the profile of re-
sponders and non-responders were largely similar, and
therefore it is thought that a possible non-response bias
would not play a major role. Low response rates are not
unusual in population based studies investigating the
prevalence of food allergy [3,5].
The gold standard for the diagnosis of FA is DBPCFC
[16]. However, DBPCFC is time-consuming, expensive,
subjects patients to potential severe allergic reactions,
requires the need for well equipped facilities and may
not be able to reproduce the conditions that occurred
when the reported allergic reaction took place [17,18].
Due to these practical problems, in normal clinical set-
tings FA is often diagnosed by a thorough medical his-
tory and a test for sensitization [17,19]. In our study,
medical history and sIgE was used to define a probable
FA since this could be performed in all participants
and outpatients. Certain participants in the community
and outpatient studies agreed to undergo DBPCFC and,
whilst a relatively small sample, no differences were seen
in the rates of either positive DBPCFC (78% and 64%,
respectively) or the objective signs between the two
groups. These data indicate that the clinical characteris-
tics of individuals with a probable FA in this population
were similar between the two populations and that the
estimates of prevalence relying only on clinical history
and sIgE will over-estimate rates of confirmed food
allergy by around 22-37%. A low participation rate inDBPCFC is also reported in other studies [5,7]. The
main reason for refusal to participate in DBPCFC in our
patients was the lack of time.
In general, it might be expected that the frequency of
severe FA in outpatients referred to a tertiary allergy
center is higher compared to the community. In this
study we observed no significant difference in the fre-
quency of severe symptoms between both groups. Of the
participants with a probable FA in the community,
40.4% had never sought medical care for their symptoms
to food and of these, 46.4% had severe symptoms upon
ingestion of the causative food (data not shown). Thus,
severe symptoms are not always a trigger for FA-patients
to seek medical care.
Conclusions
In the Netherlands, there are large differences in self-
reported FA between community and outpatients. How-
ever, Dutch community and outpatients with a probable
FA do not differ with respect to severity, causative foods,
sensitization and DBPCFC-outcome.
Abbreviations
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